Interleukin-17

Correctly identifying cytokine pathways that are dysregulated in any given rheumatology patient could lead to better use of current biologic therapies, said a presenter at the 2022 Association of Women in Rheumatology annual conference.

Although a range of biologic options are available to clinicians treating psoriatic arthritis, it crucial to know which disease domains are involved as this will “dictate treatment,” according to a presenter at the Biologic Therapies Summit.

Guselkumab is comparable to interleukin-17A and subcutaneous TNF inhibitors for efficacy, and demonstrated a better PASI response relative to other drugs, in patients with psoriatic arthritis, according to a meta-analysis published in Rheumatology.

ATLANTA — Certolizumab pegol and bimekizumab were associated with improvements ranging from work productivity to disease activity in patients with spondyloarthritic conditions, according to findings presented in three abstracts at ACR/ARP 2019.

UCB announced positive results from BE READY, the second of three phase 3 studies to report on bimekizumab this year.

ATLANTA — Guselkumab, administered either every 4 or 8 weeks, is efficacious for joint and skin symptoms, as well as physical function and quality of life, among patients with active psoriatic arthritis who are biologic-naive or previously received TNF inhibitors, according to data presented at ACR/ARP 2019.

Since 2004, World Psoriasis Day has been celebrated on Oct. 29.

Treatment with bimekizumab, an interleukin-17A and IL-17F inhibitor in adults with chronic plaque psoriasis, resulted in at least a 90% improvement in the Psoriasis Area and Severity Index and Investigator Global Assessment score of clear or almost clear, according to phase 3 results from the development program BE VIVID by UCB.

The safety and efficacy of Ilumya were maintained after 4 years of treatment among patients with plaque psoriasis enrolled in the open-label reSURFACE1 trial, according to data presented at the European Academy of Dermatology and Venereology Congress.

A significantly greater proportion of patients with psoriasis receiving guselkumab achieved a 90% reduction or more in the Psoriasis Area and Severity Index at week 48 than those receiving secukinumab, according to researchers in The Lancet.